# A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

> **NCT06346899** · — · COMPLETED · sponsor: **Takeda** · enrollment: 115 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT06346899
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-20
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06346899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06346899, "A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06346899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*